Language:
Baker McKenzie advised CureVac N.V. (Nasdaq: CVAC) on a collaboration and services agreement with Bayer AG, regarding support services for the development and delivery of CureVac's COVID-19 vaccine candidate CVnCoV, as well as certain local activities in selected countries.

CureVac will be the Marketing Authorization Holder for the vaccine, while Bayer will support CureVac with country operations within the European Union (EU) and selected additional markets. Bayer obtained options to become Marketing Authorization Holder in markets outside of Europe. With this collaboration, the two companies are combining their respective strengths. The aim is for CureVac to be in a position to ensure a worldwide supply of hundreds of millions of CVnCoV doses, once approvals are granted. The two companies will thus make an important contribution to combating the COVID-19 pandemic.

"The cooperation and service agreement with Bayer is a great success for our client. With its expertise and infrastructure, Bayer can help our client to make its vaccine candidate CVnCoV available to as many people as possible, in an even faster way, and thus help to end the pandemic", comments Dr. Constanze Ulmer-Eilfort, lead partner at Baker McKenzie in the transaction.

CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. Based on its proprietary technology, the company has built a deep clinical pipeline across the are-as of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. It is headquartered in Tübingen, Germany, and employs more than 500 people at its sites in Tübingen, Frankfurt, and Boston, USA.

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earn-ing power and create value through innovation and growth. Bayer is committed to the principles of sustaina-ble development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros.

CureVac is a long-standing client of Baker McKenzie. Under the leadership of Dr. Constanze Ulmer-Eilfort, Baker McKenzie advised CureVac, inter alia, on cooperation agreements with the Bill & Melinda Gates Foun-dation and the international vaccine alliance CEPI, on the strategic partnership with Genmab A/S for the de-velopment of mRNA-based antibody therapeutics and most recently on a strategic collaboration agreement with GlaxoSmithKline (GSK) for the research, development, manufacturing and commercialisation of up to five mRNA-based vaccines and monoclonal antibodies (mAbs) targeting infectious disease pathogens (July 2020).

Legal advisor to CureVac N.V.:
Baker McKenzie

Lead: IP: Dr. Constanze Ulmer-Eilfort (partner, Munich)

Team: Regulatory: Els Janssens (counsel, Brussels)
IP: Dr. iur. Julia Schieber (senior associate, Zurich)
Explore Our Newsroom